QMed Inc. announce Restylane(R) Lidocaine and Restylane Perlane(TM) Lidocaine as the latest additions to the Restylane range. Frown lines, wrinkles around the nose, mouth and between the eyes can be quickly managed with the new products Restylane Lidocaine and Restylane Perlane Lidocaine. Through the addition of 0.3% lidocaine the products offer maximum effect with a minimum of discomfort during treatment. Lidocaine is a swift and safe local anaesthetic that is widely used by physicians to numb treatment sites. Since all experience pain differently, it is a comfort to have the choice of a Restylane treatment with integrated pain relief. The results from a randomised, double-blind, split face study shows that 90% of the subjects assessed Restylane Perlane Lidocaine as being the more comfortable treatment with regard to pain at injection when compared to injection without the addition of lidocaine. The filler effect was shown in the same study to be equivalent to the corresponding product without lidocaine.

QMed Inc. has announced that it has filed a Form 15 with the Securities and Exchange Commission to voluntarily deregister its common stock under the Securities Exchange Act of 1934, as amended.

On May 19, 2008, QMed Inc. received a NASDAQ Staff Letter from NASDAQ, on which the Company’s common stock had been listed. The Letter indicated that the Company’s common stock would be delisted from The NASDAQ Stock Market on May 21, 2008. In a letter received by the Company on April 14, 2008, the Staff of NASDAQ previously noted several reasons to support its decision to delist the Common Stock.